FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378174635> ?p ?o ?g. }

• W4378174635 endingPage "100678" @default.
• W4378174635 startingPage "100678" @default.
• W4378174635 abstract "Rationale and ObjectiveRecent initiatives aim to improve patient satisfaction and autonomy by increasing the use of peritoneal dialysis (PD) in the United States. However, limited knowledge is available about the costs of different dialysis modalities, particularly those incurred by private insurers. In this study, we compared the costs of injectable dialysis drugs (and their oral equivalents) provided by insurers between privately insured patients receiving hemodialysis and PD.Study DesignA retrospective cohort study.Setting and ParticipantsFrom a private insurance claims database, we identified patients who started receiving PD or in-center hemodialysis between January 1, 2017, and December 31, 2020.ExposurePatients started receiving PD.OutcomesAverage annual injectable drug and aggregate expenditures and expenditure subcategories.Analytical ApproachPatients who started receiving PD were propensity matched to similar patients who started receiving hemodialysis based on the year of dialysis initiation, patient demographics, health, geography, and comorbidities. Cost ratios (CRs) were estimated from generalized linear models.ResultsWe matched 284 privately insured patients who started receiving PD 1:1 with patients started receiving in-center hemodialysis. The average annual injectable drug expenditures for hemodialysis were 2-fold higher (CR: 1.99; 95% CI, 1.62-2.44) than that for PD. Compared those receiving PD, patients receiving hemodialysis incurred significantly lower nondrug dialysis-related expenditures (0.85; 95% CI, 0.76-0.94). The average annual expenditures for non–dialysis-dependent outpatient services were significantly higher among patients who underwent in-center hemodialysis (CR: 1.44; 95% CI, 1.10-1.90). Although aggregate and inpatient hospitalization expenditures were higher for in-center hemodialysis, these differences did not reach statistical significance.LimitationsSmall sample sizes may have restricted our ability to identify differences in some cost categories.ConclusionsCompared with privately insured patients who started receiving PD, patients starting in-center hemodialysis incurred higher expenditures for injectable dialysis drugs, whereas differences in other expenditure categories varied. Recent increases in the use of PD may lead to reductions in injectable dialysis drug costs among privately insured patients.Plain Language SummaryRecent initiatives aim to improve patient satisfaction and autonomy by increasing the use of peritoneal dialysis (PD) in the United States. However, limited knowledge is available about the costs of different dialysis modalities, particularly those incurred by private insurers. In this study, we compared the costs of injectable dialysis drugs (and their oral equivalents) provided by insurers between privately insured patients receiving hemodialysis and PD. We found that the average annual injectable drug expenditures for hemodialysis were 2.0-fold higher compared with those for PD. These findings suggest that the recent increase in the use of PD may lead to reductions in injectable dialysis drug costs among privately insured patients. Recent initiatives aim to improve patient satisfaction and autonomy by increasing the use of peritoneal dialysis (PD) in the United States. However, limited knowledge is available about the costs of different dialysis modalities, particularly those incurred by private insurers. In this study, we compared the costs of injectable dialysis drugs (and their oral equivalents) provided by insurers between privately insured patients receiving hemodialysis and PD. A retrospective cohort study. From a private insurance claims database, we identified patients who started receiving PD or in-center hemodialysis between January 1, 2017, and December 31, 2020. Patients started receiving PD. Average annual injectable drug and aggregate expenditures and expenditure subcategories. Patients who started receiving PD were propensity matched to similar patients who started receiving hemodialysis based on the year of dialysis initiation, patient demographics, health, geography, and comorbidities. Cost ratios (CRs) were estimated from generalized linear models. We matched 284 privately insured patients who started receiving PD 1:1 with patients started receiving in-center hemodialysis. The average annual injectable drug expenditures for hemodialysis were 2-fold higher (CR: 1.99; 95% CI, 1.62-2.44) than that for PD. Compared those receiving PD, patients receiving hemodialysis incurred significantly lower nondrug dialysis-related expenditures (0.85; 95% CI, 0.76-0.94). The average annual expenditures for non–dialysis-dependent outpatient services were significantly higher among patients who underwent in-center hemodialysis (CR: 1.44; 95% CI, 1.10-1.90). Although aggregate and inpatient hospitalization expenditures were higher for in-center hemodialysis, these differences did not reach statistical significance. Small sample sizes may have restricted our ability to identify differences in some cost categories. Compared with privately insured patients who started receiving PD, patients starting in-center hemodialysis incurred higher expenditures for injectable dialysis drugs, whereas differences in other expenditure categories varied. Recent increases in the use of PD may lead to reductions in injectable dialysis drug costs among privately insured patients." @default.
• W4378174635 created "2023-05-26" @default.
• W4378174635 creator A5013444776 @default.
• W4378174635 creator A5014965271 @default.
• W4378174635 creator A5038929161 @default.
• W4378174635 creator A5042059087 @default.
• W4378174635 creator A5058491521 @default.
• W4378174635 date "2023-08-01" @default.
• W4378174635 modified "2023-09-30" @default.
• W4378174635 title "Hemodialysis Versus Peritoneal Dialysis Drug Expenditures: A Comparison Within the Private Insurance Market" @default.
• W4378174635 cites W1493091238 @default.
• W4378174635 cites W2057001161 @default.
• W4378174635 cites W2057780602 @default.
• W4378174635 cites W2088798356 @default.
• W4378174635 cites W2114657900 @default.
• W4378174635 cites W2124701107 @default.
• W4378174635 cites W2126049444 @default.
• W4378174635 cites W2280087205 @default.
• W4378174635 cites W2322818066 @default.
• W4378174635 cites W2418444286 @default.
• W4378174635 cites W2612251907 @default.
• W4378174635 cites W2613434846 @default.
• W4378174635 cites W3139466025 @default.
• W4378174635 cites W3188724005 @default.
• W4378174635 cites W4220802540 @default.
• W4378174635 cites W4293825636 @default.
• W4378174635 doi "https://doi.org/10.1016/j.xkme.2023.100678" @default.
• W4378174635 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37455793" @default.
• W4378174635 hasPublicationYear "2023" @default.
• W4378174635 type Work @default.
• W4378174635 citedByCount "0" @default.
• W4378174635 crossrefType "journal-article" @default.
• W4378174635 hasAuthorship W4378174635A5013444776 @default.
• W4378174635 hasAuthorship W4378174635A5014965271 @default.
• W4378174635 hasAuthorship W4378174635A5038929161 @default.
• W4378174635 hasAuthorship W4378174635A5042059087 @default.
• W4378174635 hasAuthorship W4378174635A5058491521 @default.
• W4378174635 hasBestOaLocation W43781746351 @default.
• W4378174635 hasConcept C126322002 @default.
• W4378174635 hasConcept C194828623 @default.
• W4378174635 hasConcept C2776337213 @default.
• W4378174635 hasConcept C2778063415 @default.
• W4378174635 hasConcept C2779056158 @default.
• W4378174635 hasConcept C2779978075 @default.
• W4378174635 hasConcept C71924100 @default.
• W4378174635 hasConceptScore W4378174635C126322002 @default.
• W4378174635 hasConceptScore W4378174635C194828623 @default.
• W4378174635 hasConceptScore W4378174635C2776337213 @default.
• W4378174635 hasConceptScore W4378174635C2778063415 @default.
• W4378174635 hasConceptScore W4378174635C2779056158 @default.
• W4378174635 hasConceptScore W4378174635C2779978075 @default.
• W4378174635 hasConceptScore W4378174635C71924100 @default.
• W4378174635 hasIssue "8" @default.
• W4378174635 hasLocation W43781746351 @default.
• W4378174635 hasLocation W43781746352 @default.
• W4378174635 hasOpenAccess W4378174635 @default.
• W4378174635 hasPrimaryLocation W43781746351 @default.
• W4378174635 hasRelatedWork W1586411312 @default.
• W4378174635 hasRelatedWork W1966665808 @default.
• W4378174635 hasRelatedWork W2029370573 @default.
• W4378174635 hasRelatedWork W2057177196 @default.
• W4378174635 hasRelatedWork W2062682027 @default.
• W4378174635 hasRelatedWork W2124701107 @default.
• W4378174635 hasRelatedWork W2321507483 @default.
• W4378174635 hasRelatedWork W2355879010 @default.
• W4378174635 hasRelatedWork W2417459137 @default.
• W4378174635 hasRelatedWork W3031983961 @default.
• W4378174635 hasVolume "5" @default.
• W4378174635 isParatext "false" @default.
• W4378174635 isRetracted "false" @default.
• W4378174635 workType "article" @default.